SSGJ-707 + 5-fluorouracil + calcium folinate + oxaliplatin

SSGJ-707 + 5-fluorouracil + calcium folinate + oxaliplatin is an investigational **combination therapy** comprising a bispecific antibody (SSGJ-707, targeting PD-1 and VEGF)[1][5], the antimetabolite chemotherapeutic 5-fluorouracil (5-FU)[2][6], the folate analog calcium folinate (also called folinic acid or leucovorin), and the platinum-based chemotherapy oxaliplatin. This regimen is being developed for the treatment of advanced or metastatic solid tumors, particularly metastatic colorectal cancer and non-small cell lung cancer[1][5][7]. - **SSGJ-707** is a bispecific antibody that inhibits both PD-1 (programmed cell death protein 1), an immune checkpoint, and VEGF (vascular endothelial growth factor), an angiogenesis factor. The combined blockade aims to enhance antitumor immune response while inhibiting tumor vascularization[1][5]. - **5-fluorouracil** is a small-molecule antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis, and is incorporated into RNA, leading to cytotoxicity in rapidly dividing tumor cells[2][6]. - **Calcium folinate** potentiates the cytotoxic effects of 5-FU by stabilizing the ternary complex with thymidylate synthase, thereby enhancing inhibition of DNA synthesis[2][6]. - **Oxaliplatin** is a platinum-based antineoplastic agent that forms DNA crosslinks, leading to apoptosis in cancer cells. Combination regimens using 5-FU, calcium folinate, and oxaliplatin (such as FOLFOX) are routinely used as standard chemotherapy backbones in colorectal cancer. SSGJ-707 is being studied as an addition to this backbone to improve efficacy in the first-line or relapsed/refractory metastatic setting[5][7]. The combination is currently in **Phase 2/3 clinical trials** for metastatic colorectal cancer and non-small cell lung cancer[1][3][5][7]. SSGJ-707 was developed by 3SBio and is being co-developed/licensed with Pfizer for ex-China regions[1][5].

Other names

SSGJ-707 + 5-FU + folinic acid + oxaliplatin